Please use this identifier to cite or link to this item: http://hdl.handle.net/10261/213437
Share/Export:
logo share SHARE logo core CORE BASE
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE
Title

Clinical utility of plasma-based digital next-generation sequencing in oncogene-driven non-small-cell lung cancer patients with tyrosine kinase inhibitor resistance

AuthorsZugazagoitia, Jon; Gómez-Rueda, Ana; Jantus-Lewintre, Eloisa; Isla, María Dolores; Camps, Carlos; Ramos, Inmaculada; Trigo, José Manuel; Bernabé Caro, Reyes; Juan-Vidal, Óscar; Sánchez-Torres, J. M.; García-Campelo, R.; Provencio, Mariano; Felip, Enriqueta; Castro, Javier de; Faul, Iris; Lanman, R. B.; Ponce-Aix, Santiago; Paz-Ares, Luis CSIC ORCID; Garrido, Pilar
KeywordsOncogene-driven NSCLC
TKI resistance
Osimertinib
ctDNA
Digital next-generation sequencing
Issue DateAug-2019
PublisherElsevier
CitationLung Cancer 134: 72-78 (2019)
Abstract[Objectives] Resistance to tyrosine-kinase inhibitors (TKIs) is a clinical challenge in patients with oncogene-driven non-small-cell lung cancers (NSCLC). We have analyzed the utility of next-generation sequencing (NGS) of cell-free circulating tumor DNA (ctDNA) to impact the clinical care of patients with TKI resistance.
[Materials and methods] We conducted a multi-institutional prospective study including consecutive EGFR, ALK, or ROS1-altered NSCLC patients with TKI resistance from 12 Spanish institutions. Post-progression ctDNA NGS was performed by Guardant Health (Guardant360 assay).
[Results] We included 53 patients separated in 3 cohorts: 31 EGFR-mutant NSCLCs with first/second-generation TKI resistance (cohort 1), 15 EGFR T790M + NSCLCs with osimertinib resistance (cohort 2), and 7 ALK/ROS1-rearranged NSCLCs with crizotinib and/or next-generation TKI resistance (cohort 3). Besides Guardant360, 22 patients from cohort 1 (71%) underwent post-progression tumor biopsies and/or alternative plasma-based genotyping. In the entire study population, 34 patients (64%) had reliable evidence of tumor-DNA shed for resistance assessment, and 24 patients (45%) had actionable alterations. Target-independent pathogenic alterations were frequently detected, particularly at osimertinib resistance. Eleven patients (20%) received subsequent molecular-guided therapies indicated by plasma NGS alone (n = 9, 17%), or plasma NGS and tissue sequencing (n = 2, 4%), deriving the expected clinical benefit. Of these, 9 had EGFR T790 M mutation and received osimertinib, 1 had ALK G1202R mutation and received lorlatinib, and 1 had ROS1 G2032R mutation and received cabozantinib. Two additional cases from cohort 1 (6%) had undetectable EGFR T790 M by Guardant360 but were T790M + by tissue and BEAMing digital PCR respectively, and also received osimertinib.
[Conclusion] NGS of ctDNA detects actionable alterations in a large proportion of oncogene-driven NSCLC patients with TKI resistance, and can be used to guide subsequent treatments as a complement or alternative to tissue or PCR-based plasma genotyping in the real-world clinical setting.
Publisher version (URL)https://doi.org/10.1016/j.lungcan.2019.05.032
URIhttp://hdl.handle.net/10261/213437
DOI10.1016/j.lungcan.2019.05.032
ISSN0169-5002
Appears in Collections:(IBIS) Artículos




Files in This Item:
File Description SizeFormat
accesoRestringido.pdf59,24 kBAdobe PDFThumbnail
View/Open
Show full item record
Review this work

SCOPUSTM   
Citations

13
checked on May 23, 2022

WEB OF SCIENCETM
Citations

12
checked on May 25, 2022

Page view(s)

112
checked on May 26, 2022

Download(s)

23
checked on May 26, 2022

Google ScholarTM

Check

Altmetric

Dimensions


WARNING: Items in Digital.CSIC are protected by copyright, with all rights reserved, unless otherwise indicated.